EXPERIENCE OF COMBINED USE OF PLASMAPHERESIS AND NONSPECIFIC IMMUNOTHERAPY IN THE COMPLEX TREATMENT OF LOCALLY ADVANCED FORMS OF CERVICAL CANCER

Abstract

The purpose of this study was to study the effectiveness of the use of efferent methods of treatment (plasmapheresis) and the immunomodulator "Allokin-alpha" in the program of preoperative chemotherapy in patients with locally advanced cervical cancer. The study included 79 patients with locally advanced cervical cancer T2a-2bN0-1M0 gy 2. All patients received neoadjuvant chemotherapy according to the scheme: cisplatin and bleomycin. Patients in the control group were treated directly with neoadjuvant chemotherapy. All patients of the main group had a plasmapheresis session before the course of neoadjuvant chemotherapy. Patients of the second main subgroup additionally underwent a course of nonspecific immunotherapy with the drug "Allokin-alpha". The dynamics of immunological and biochemical blood parameters were studied in all patients during treatment. Statistical data processing was performed using the Statistica for Windows v.10.0 software package. It has been proved that neoadjuvant chemotherapy in combination with plasmapheresis and nonspecific immunotherapy in the treatment of patients with locally advanced cervical cancer is pathogenetically justified, because it allows to enhance the effect of cytostatics on the tumor and significantly increases the overall 5-year survival of patients. The immunological data obtained during the use of plasmapheresis and Allokin-alpha in the course of chemotherapy can be regarded as prognostically favorable and reflecting the clinical dynamics of patients with cervical cancer. It seems appropriate to include plasmapheresis and immunomodulation with an interferon inducer in the complex treatment of patients with cervical cancer.